Wedbush Predicts Weaker Earnings for TScan Therapeutics

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Analysts at Wedbush dropped their FY2026 earnings per share (EPS) estimates for shares of TScan Therapeutics in a research note issued to investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.97) for the year, down from their prior forecast of ($0.96). Wedbush has a “Outperform” rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ FY2027 earnings at ($1.02) EPS and FY2028 earnings at ($0.94) EPS.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a research report on Wednesday.

TScan Therapeutics Stock Down 1.9 %

TCRX stock opened at $3.02 on Friday. TScan Therapeutics has a fifty-two week low of $2.60 and a fifty-two week high of $9.69. The company’s 50 day moving average price is $4.87 and its 200 day moving average price is $5.91. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Stifel Financial Corp grew its stake in TScan Therapeutics by 3.9% in the 3rd quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock valued at $494,000 after acquiring an additional 3,733 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $70,000. MetLife Investment Management LLC raised its position in shares of TScan Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $90,000. Finally, SG Americas Securities LLC acquired a new stake in TScan Therapeutics during the 3rd quarter valued at $78,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other TScan Therapeutics news, Director Barbara Klencke bought 5,000 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was acquired at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares of the company’s stock, valued at approximately $238,050. This represents a 12.50 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.76% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.